These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 14508120)

  • 21. How to revive breakthrough innovation in the pharmaceutical industry.
    Munos BH; Chin WW
    Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indian pharma enters the global arena.
    Singh S
    Cell; 2007 Mar; 128(5):811-4. PubMed ID: 17350563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The difficulties industry is facing with investigators.
    Blackledge GR
    Eur J Cancer; 2005 Oct; 41(15):2210-2. PubMed ID: 16214043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How to utilize academic research efforts in cancer drug discovery.
    Bérubé G
    Expert Opin Drug Discov; 2019 Apr; 14(4):331-334. PubMed ID: 30784328
    [No Abstract]   [Full Text] [Related]  

  • 26. Proteomics-based anticancer drug discovery and development.
    Jain KK
    Technol Cancer Res Treat; 2002 Aug; 1(4):231-6. PubMed ID: 12625781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.
    Fitzgerald GA
    Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficiency of antisense oligonucleotide drug discovery.
    Bennett CF
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):215-24. PubMed ID: 12162703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discontinued drugs in 2008: oncology drugs.
    Williams R
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1581-94. PubMed ID: 19663760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigator-initiated trials of targeted oncology agents: why independent research is at risk?
    Bergmann L; Berns B; Dalgleish AG; von Euler M; Hecht TT; Lappin GL; Reed N; Palmeri S; Smyth J; Embacher-Aichorn S; Zwierzina H;
    Ann Oncol; 2010 Aug; 21(8):1573-1578. PubMed ID: 20133383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging science, emerging ethical issues: who should fund innate alloimmunity-suppressing drugs?
    Land WG; Gutmann T; Daar AS
    Acta Chir Belg; 2008; 108(1):73-82. PubMed ID: 18411578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective.
    Wong EH; Yocca F; Smith MA; Lee CM
    Int J Neuropsychopharmacol; 2010 Oct; 13(9):1269-84. PubMed ID: 20716397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No immediate pain relief for the pharmaceutical industry.
    Ahlborn H; Henderson S; Davies N
    Curr Opin Drug Discov Devel; 2005 May; 8(3):384-91. PubMed ID: 15892254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An audience with...Joseph Bolen. Interview by Bethan Hughes.
    Bolen J
    Nat Rev Drug Discov; 2009 Aug; 8(8):608. PubMed ID: 19644470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Collaborative approaches to anticancer drug discovery and development: a Cancer Research UK perspective.
    Williams RJ; Walker I; Takle AK
    Drug Discov Today; 2012 Mar; 17(5-6):185-7. PubMed ID: 22314099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Metaboloepigenetic Dimension of Cancer Stem Cells: Evaluating the Market Potential for New Metabostemness-Targeting Oncology Drugs.
    Menendez JA
    Curr Pharm Des; 2015; 21(25):3644-53. PubMed ID: 26166605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iconix Pharmaceuticals, Inc.--removing barriers to efficient drug discovery through chemogenomics.
    Engelberg A
    Pharmacogenomics; 2004 Sep; 5(6):741-4. PubMed ID: 15335294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.